Humana faces significant challenges with rising denial rates and customer disenrollment, which have led to a sharp decline in stock value and profitability. Medicare Advantage's struggles, including ...
Zacks Investment Research on MSN
Humana partners with Atlas to enhance cancer care for seniors
Humana Inc. HUM recently unveiled a tie-up with Atlas Oncology Partners in a bid to provide enhanced cancer care, ...
Medicare Advantage insurers fully or partially denied 7.4% of prior authorization requests in 2022, an increase compared to the previous three years, according to an analysis by health policy research ...
The healthcare sector is a haven to trade amid market volatility, with the Healthcare sector ETF down only 3.3% YTD compared to the S&P 500's 15% decline. Humana's stock has shown resilience, boosted ...
Early prescription refills by U.S. pharmacies cost Medicare and patients $3B in 2021–2023, with mail-order pharmacies run by UnitedHealth (UNH) and Humana (HUM) leading the cost overruns, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback